The MMEDS Act of 2025 adds a new Subchapter AA to the Internal Revenue Code that creates targeted tax incentives for medical manufacturing located in designated economically distressed census tracts. The package includes a facility-level credit equal to a percentage of wages, allocable fringe benefits, and depreciation/amortization tied to qualified medical manufacturing property, plus a separate credit for purchasing goods and services produced inside those zones.
The bill also raises those percentages for facilities that repatriate production judged to pose national supply‑chain risk and for facilities producing designated “population health products.”
Beyond tax law, the bill amends the Public Health Service Act to expand the definition of priority countermeasures and to direct HHS to prioritize and coordinate development and distribution of products that protect vulnerable populations in epidemics and pandemics. The result is a hybrid industrial‑and‑health security bill that steers tax expenditures toward high‑poverty tracts while giving HHS explicit direction to support products for at‑risk groups — a mix that will matter to tax planners, manufacturers, state economic development officials, and HHS/IRS implementers.
At a Glance
What It Does
Adds Subchapter AA to the IRC establishing a refundable credit equal to 40% of a combination of qualified wages, allocable fringe, and depreciation/amortization for medical manufacturing in designated economically distressed zones; creates a separate purchase credit (30% for third‑party suppliers, 5% for related parties) for goods/services bought from those zones. It increases credit percentages for repatriated and designated population‑health facilities and allows an alternative election to expense qualifying property.
Who It Affects
Domestic manufacturers of FDA‑regulated drugs, biologics, and devices with operations or suppliers in qualifying high‑poverty census tracts; suppliers and service providers located in those tracts; state and local governments that apply to have tracts designated; and federal agencies (IRS, HHS, Commerce) charged with implementing designations and definitions.
Why It Matters
This bill ties federal tax incentives to place-based industrial policy and health security goals, potentially shifting where drug and device production happens and boosting investment in chronically distressed communities. It also expands HHS’s remit to prioritize products for vulnerable populations — creating new intersections between tax policy, procurement priorities, and public‑health planning.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The MMEDS Act carves out a new, standalone tax regime for medical manufacturing activity inside census tracts the bill defines as ‘economically distressed zones.’ At the core is a credit that equals 40 percent of three categories: wages paid to employees whose principal place of work is a qualified medical manufacturing facility in an eligible tract; allocable employer fringe benefits for those employees; and depreciation or amortization tied to qualified facility property used in research, development, or production of medical products or essential components. The bill limits the wages counted per employee to the Social Security contribution and benefit base for the relevant calendar year and excludes wages that are actually treated as fringe benefits.
A second incentive rewards U.S. manufacturers that buy products or services produced within an economically distressed zone. That purchase credit pays an ‘applicable percentage’ of qualifying acquisitions — 30 percent for unrelated sellers and only 5 percent for related parties — and covers things integrated into finished medical products as well as necessary services such as packaging.
The statute treats members of an affiliated group as a single taxpayer for credit calculations, which affects how companies with multiple entities claim and allocate benefits.The bill raises the stakes for certain strategic manufacturing: it directs higher credit percentages for two categories — ‘qualified repatriated’ facilities (production relocated from foreign jurisdictions deemed supply‑chain risks by USTR) and facilities producing HHS‑designated ‘population health products.’ For those facilities, the statute increases the wage/fringe/depreciation credit and gives larger purchase credits; it also offers an elective tax treatment that allows a taxpayer to expense qualifying facility property (effectively enabling full bonus depreciation) instead of using the depreciation component of the credit.On the geographic side, tracts with a poverty rate of at least 30 percent for each of the last five years get automatic designation as economically distressed zones effective on enactment; other tracts can be designated after a state or local application that includes a strategic plan and community partnership commitments. Designations last 15 years; the Secretary of the Treasury and Commerce must issue a list and guidance quickly (the bill sets 30‑ and 60‑day targets for initial actions).
Finally, the measure amends the Public Health Service Act to add statutory definitions (population health products, vulnerable American populations), to expand the scope of priority countermeasures, to direct HHS prioritization for at‑risk groups, and to require a short HHS report on disproportionate harms and the need for incentives.
The Five Things You Need to Know
The base tax credit equals 40% of the sum of (a) qualifying economically distressed zone wages, (b) allocable employee fringe benefit expenses, and (c) depreciation/amortization for qualified medical manufacturing facility property.
Wages counted toward the credit are capped per employee at the Social Security contribution and benefit base for the calendar year in which the taxable year begins; part‑time or non‑continuous employees are prorated.
The purchase credit pays 30% of qualifying purchases from unrelated suppliers located in an economically distressed zone but only 5% for purchases from related parties.
For facilities that repatriate production from countries USTR flags as supply‑chain risks, and for HHS‑designated population health product facilities, the bill raises the credit percentages and permits an election to expense qualifying property (100% bonus‑depreciation treatment) in lieu of the depreciation component.
Census tracts with a 5‑year poverty rate of at least 30% are automatically designated as economically distressed zones on enactment; designations last 15 years and other tracts may be designated after a state/local application with a strategic development plan.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Creates a new IRC Subchapter AA for medical manufacturing in distressed zones
The bill adds a self‑contained Subchapter AA to Chapter 1 of the Internal Revenue Code titled 'Medical Manufacturing in Economically Distressed Zones.' That subchapter houses the wage/fringe/depreciation credit, the purchase credit, special rules for strategic facilities, and the statutory definition and process for designating economically distressed zones. Making a separate subchapter concentrates the new rules, simplifies cross‑references for Treasury, and signals these incentives are tightly targeted to medical manufacturing rather than general investment.
Facility credit: 40% of wages, allocable fringe, and qualified property depreciation
This section defines the principal credit: 40% of three buckets tied to activity in a qualified medical manufacturing facility inside a designated tract. It specifies what counts as an eligible facility (research, development, production of FDA‑regulated drugs/devices or essential components like APIs and biologic ingredients) and defines how to treat fringe benefits, depreciation, and affiliated groups. The statutory wage cap uses the Social Security taxable wage base, and the provision denies double‑counting against the R&D credit and any other provision the Secretary finds substantially similar.
Supplier/purchase credit to buy zone‑made inputs and services
This provision lets eligible U.S. medical manufacturers claim a credit equal to an 'applicable percentage' of amounts paid to providers inside the zone for qualified products or services that are integrated into or necessary for producing a medical product. The law distinguishes related parties (low 5% rate) from unrelated suppliers (30% rate) to limit intra‑group routing of purchases solely to capture subsidies. 'Qualified product or service' explicitly covers production and services such as packaging performed inside the designated tract.
Enhanced rates and bonus‑expense option for repatriated and population‑health facilities
The bill increases credit percentages for two targeted priorities: facilities that repatriate production from foreign jurisdictions designated by USTR as supply‑chain risks, and those producing HHS‑identified 'population health products.' It also permits taxpayers to elect an alternative tax treatment that treats qualifying facility property as eligible for 100% bonus expensing under section 168(k) instead of including that property in the depreciation component of the credit — a timing and cash‑flow choice with meaningful tax planning implications.
How economically distressed zones are designated and how long benefits run
Designation uses a two‑track test. Tracts with a 5‑year poverty rate at or above 30% are automatically treated as distressed starting on enactment. Other tracts can qualify subject to a joint Treasury/Commerce determination after a state or local application that supplies a strategic development plan, community partnership evidence, and assurances against harmful relocations. Designations last 15 years; the bill requires Treasury to publish initial lists and guidance on tight deadlines (30 and 60 days) and explicitly includes U.S. territories.
Expands HHS authorities and definitions for population health products and vulnerable populations
The statute expands the definition of 'qualified countermeasure' and creates a statutory category, 'population health products,' to cover drugs that reduce disproportionate harm when non‑communicable diseases intersect with pandemics. It authorizes HHS to prioritize research, advanced development, manufacturing and stockpiling for these threats, instructs coordination with CMS, DOD, VA, and FDA to accelerate distribution to vulnerable groups, and requires a short report to Congress analyzing disproportionate harms and whether additional incentives are warranted.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Domestic medical manufacturers that locate production or R&D inside designated economically distressed tracts — they qualify for the 40% credit on wages, eligible fringe, and related depreciation and can increase cash flow or reduce tax liability.
- Local suppliers and contract service providers operating within designated tracts — sales to eligible U.S. manufacturers qualify for a purchase credit (30% for unrelated buyers), creating demand for zone‑based inputs and services.
- State and local economic development authorities — they gain a financial lever to attract pharmaceutical, biotech, and device investment to high‑poverty neighborhoods when preparing applications and strategic plans.
- Vulnerable American populations — by statute HHS must prioritize development and distribution of population‑health products for groups such as children, older adults, pregnant women, and minority populations, which could improve access to countermeasures designed for at‑risk groups.
- Tax and legal advisors — the new subchapter creates planning and compliance work (allocation rules, aggregation, elections), increasing demand for professional services.
Who Bears the Cost
- Federal government/treasury — the program creates substantial, unspecified tax expenditures (credits and bonus depreciation elections) that will reduce federal receipts; the bill contains no offset.
- IRS, HHS, and Commerce — these agencies must issue guidance, administer designations, evaluate applications, and coordinate cross‑agency priorities under tight statutory deadlines, imposing administrative burdens and potential resource needs.
- Manufacturers and suppliers outside designated tracts — firms without access to the zone credits face a relative competitive disadvantage and may see investment shift toward eligible tracts.
- Companies that rely on related‑party supply chains — the low 5% related‑party purchase credit discourages using intra‑group transfers to capture subsidies, and related entities will face increased documentation and transfer‑pricing scrutiny.
- State and local governments — preparing designation applications and strategic plans, and meeting community partnership and resource‑commitment requirements, will require time, staff, and potentially matching funding.
Key Issues
The Core Tension
The central dilemma is between speed and targeting: the bill tries to jump‑start domestic medical production by concentrating large tax subsidies in chronically distressed tracts and by prioritizing products for vulnerable populations, but doing so quickly and narrowly risks large, poorly controlled federal spending, program gaming (relocations or intra‑group structuring), and administrative overload; balancing urgent supply‑chain resilience with careful fiscal and compliance safeguards is the unresolved trade‑off.
The bill blends place‑based tax incentives with health‑security policy, but it leaves several implementation questions that could materially affect who benefits and the program’s fiscal cost. Key drafting frictions include an undefined catchall denying 'double benefits' against 'any other provision determined by the Secretary to be substantially similar' — that gives Treasury broad discretion but no statutory standard for what counts as substantially similar to this new credit.
The wage cap ties the creditable wage to the Social Security taxable wage base, which limits the credit’s value for higher‑paid personnel and incentivizes using lower‑wage labor or shifting pay into non‑wage compensation that qualifies as allocable fringe; allocation rules for those fringe costs are operationally complex and will invite disputes.
Operational timelines are aggressive: the Treasury Secretary must publish an initial list of automatically eligible tracts within 30 days and issue other designation guidance within 60 days. Those deadlines may be unrealistic given the need to reconcile census and local data, and the Commerce/Treasury review for additional tracts requires subjective judgments about 'pervasive poverty' and 'general distress.' The special‑rate provisions for repatriated and population‑health facilities raise their own tensions: designers of the statute wrote increased percentages but the text contains substitution language that is not fully consistent in how it maps to the purchase credit rates — a drafting ambiguity that will need resolution before taxpayers can rely on enhanced rates.
Finally, the 15‑year designation window and the exclusion against assisting relocations create enforcement challenges: regulators will need to police whether incentives are merely subsidizing movement of jobs from one vulnerable community to another or are truly net new investment.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.